Radiation lethality enhancement with 9-aminocamptothecin: Comparison to other topoisomerase I inhibitors

John P. Lamond, Meizhi Wang, Timothy J. Kinsella, David A. Boothman

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Purpose: Preclinical studies have demonstrated differences in potency, solubility, and tumor specific activity among the camptothecin (CPT) analogues. 9-Aminocamptothecin (9-AC) has demonstrated greater potency in animal studies than other clinically available Topoisomerase I (Topo I) inhibitors. We sought to determine: (a) if 9-AC enhanced the lethal effects of ionizing radiation to a greater extent than other Topo I inhibitors; and (b) the biological and biochemical characteristics of the enhancement. Methods and Materials: Quiescent radioresistant human melanoma (U1-Mel) cells were x-irradiated (1-7 Gy) and exposed to various concentrations of 9-AC (0.1 -100 μM), either before (for 4 h), during, or after (for 4 h) irradiation. Survival was determined via colony forming assays and normalized to correct for drug cytotoxicity. The effects of 9-AC on radiation-related potential lethal damage repair (PLDR) was also measured. A modification of the SDS-KCl assay was used to quantify DNA-Topo I complexes. Results: Enhancement of radiation lethality was observed using confluent U1-Mel cells. The sensitizer enhancement ratio (SER) after a 4 h postirradiation exposure of 10 μM 9-AC was 2.5 at 10% survival. Toxicity from the drug alone was greater than topotecan (TPT), but less than CPT. The radiation synergy effect was: (a) dependent on drug concentration (≤ 2 μM); (b) dependent on timing, with enhancement present only when the drug was present at the time of, or shortly after, radiation; and (c) irreversible, with inhibition of PLDR. Exposure to 9-AC during or after irradiation substantially elevated the number of DNA- Topo I complexes (four- to tenfold) over control levels and correlated with enhanced loss of survival. Conclusion: 9-Aminocamptothecin enhanced radiation lethality in vitro at low drug concentrations with characteristics similar to other Topo I inhibitors. A greater SER, but greater lethality with the drug alone, was obtained in comparison to TPT. The clinical implications of these findings remain unexplored.

Original languageEnglish (US)
Pages (from-to)369-376
Number of pages8
JournalInternational Journal of Radiation Oncology Biology Physics
Volume36
Issue number2
DOIs
StatePublished - Sep 1 1996

Fingerprint

9-aminocamptothecin
Topoisomerase I Inhibitors
lethality
inhibitors
drugs
Radiation
augmentation
radiation
Topotecan
Camptothecin
Type I DNA Topoisomerase
Pharmaceutical Preparations
deoxyribonucleic acid
Survival
damage
irradiation
radiation effects
cells
toxicity
ionizing radiation

Keywords

  • 9-Aminocamptothecin
  • DNA repair
  • PLDR
  • Topoisomerase I

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Radiation lethality enhancement with 9-aminocamptothecin : Comparison to other topoisomerase I inhibitors. / Lamond, John P.; Wang, Meizhi; Kinsella, Timothy J.; Boothman, David A.

In: International Journal of Radiation Oncology Biology Physics, Vol. 36, No. 2, 01.09.1996, p. 369-376.

Research output: Contribution to journalArticle

Lamond, John P. ; Wang, Meizhi ; Kinsella, Timothy J. ; Boothman, David A. / Radiation lethality enhancement with 9-aminocamptothecin : Comparison to other topoisomerase I inhibitors. In: International Journal of Radiation Oncology Biology Physics. 1996 ; Vol. 36, No. 2. pp. 369-376.
@article{67d66495ab7a4a94b87ad6e6850549fa,
title = "Radiation lethality enhancement with 9-aminocamptothecin: Comparison to other topoisomerase I inhibitors",
abstract = "Purpose: Preclinical studies have demonstrated differences in potency, solubility, and tumor specific activity among the camptothecin (CPT) analogues. 9-Aminocamptothecin (9-AC) has demonstrated greater potency in animal studies than other clinically available Topoisomerase I (Topo I) inhibitors. We sought to determine: (a) if 9-AC enhanced the lethal effects of ionizing radiation to a greater extent than other Topo I inhibitors; and (b) the biological and biochemical characteristics of the enhancement. Methods and Materials: Quiescent radioresistant human melanoma (U1-Mel) cells were x-irradiated (1-7 Gy) and exposed to various concentrations of 9-AC (0.1 -100 μM), either before (for 4 h), during, or after (for 4 h) irradiation. Survival was determined via colony forming assays and normalized to correct for drug cytotoxicity. The effects of 9-AC on radiation-related potential lethal damage repair (PLDR) was also measured. A modification of the SDS-KCl assay was used to quantify DNA-Topo I complexes. Results: Enhancement of radiation lethality was observed using confluent U1-Mel cells. The sensitizer enhancement ratio (SER) after a 4 h postirradiation exposure of 10 μM 9-AC was 2.5 at 10{\%} survival. Toxicity from the drug alone was greater than topotecan (TPT), but less than CPT. The radiation synergy effect was: (a) dependent on drug concentration (≤ 2 μM); (b) dependent on timing, with enhancement present only when the drug was present at the time of, or shortly after, radiation; and (c) irreversible, with inhibition of PLDR. Exposure to 9-AC during or after irradiation substantially elevated the number of DNA- Topo I complexes (four- to tenfold) over control levels and correlated with enhanced loss of survival. Conclusion: 9-Aminocamptothecin enhanced radiation lethality in vitro at low drug concentrations with characteristics similar to other Topo I inhibitors. A greater SER, but greater lethality with the drug alone, was obtained in comparison to TPT. The clinical implications of these findings remain unexplored.",
keywords = "9-Aminocamptothecin, DNA repair, PLDR, Topoisomerase I",
author = "Lamond, {John P.} and Meizhi Wang and Kinsella, {Timothy J.} and Boothman, {David A.}",
year = "1996",
month = "9",
day = "1",
doi = "10.1016/S0360-3016(96)00326-4",
language = "English (US)",
volume = "36",
pages = "369--376",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Radiation lethality enhancement with 9-aminocamptothecin

T2 - Comparison to other topoisomerase I inhibitors

AU - Lamond, John P.

AU - Wang, Meizhi

AU - Kinsella, Timothy J.

AU - Boothman, David A.

PY - 1996/9/1

Y1 - 1996/9/1

N2 - Purpose: Preclinical studies have demonstrated differences in potency, solubility, and tumor specific activity among the camptothecin (CPT) analogues. 9-Aminocamptothecin (9-AC) has demonstrated greater potency in animal studies than other clinically available Topoisomerase I (Topo I) inhibitors. We sought to determine: (a) if 9-AC enhanced the lethal effects of ionizing radiation to a greater extent than other Topo I inhibitors; and (b) the biological and biochemical characteristics of the enhancement. Methods and Materials: Quiescent radioresistant human melanoma (U1-Mel) cells were x-irradiated (1-7 Gy) and exposed to various concentrations of 9-AC (0.1 -100 μM), either before (for 4 h), during, or after (for 4 h) irradiation. Survival was determined via colony forming assays and normalized to correct for drug cytotoxicity. The effects of 9-AC on radiation-related potential lethal damage repair (PLDR) was also measured. A modification of the SDS-KCl assay was used to quantify DNA-Topo I complexes. Results: Enhancement of radiation lethality was observed using confluent U1-Mel cells. The sensitizer enhancement ratio (SER) after a 4 h postirradiation exposure of 10 μM 9-AC was 2.5 at 10% survival. Toxicity from the drug alone was greater than topotecan (TPT), but less than CPT. The radiation synergy effect was: (a) dependent on drug concentration (≤ 2 μM); (b) dependent on timing, with enhancement present only when the drug was present at the time of, or shortly after, radiation; and (c) irreversible, with inhibition of PLDR. Exposure to 9-AC during or after irradiation substantially elevated the number of DNA- Topo I complexes (four- to tenfold) over control levels and correlated with enhanced loss of survival. Conclusion: 9-Aminocamptothecin enhanced radiation lethality in vitro at low drug concentrations with characteristics similar to other Topo I inhibitors. A greater SER, but greater lethality with the drug alone, was obtained in comparison to TPT. The clinical implications of these findings remain unexplored.

AB - Purpose: Preclinical studies have demonstrated differences in potency, solubility, and tumor specific activity among the camptothecin (CPT) analogues. 9-Aminocamptothecin (9-AC) has demonstrated greater potency in animal studies than other clinically available Topoisomerase I (Topo I) inhibitors. We sought to determine: (a) if 9-AC enhanced the lethal effects of ionizing radiation to a greater extent than other Topo I inhibitors; and (b) the biological and biochemical characteristics of the enhancement. Methods and Materials: Quiescent radioresistant human melanoma (U1-Mel) cells were x-irradiated (1-7 Gy) and exposed to various concentrations of 9-AC (0.1 -100 μM), either before (for 4 h), during, or after (for 4 h) irradiation. Survival was determined via colony forming assays and normalized to correct for drug cytotoxicity. The effects of 9-AC on radiation-related potential lethal damage repair (PLDR) was also measured. A modification of the SDS-KCl assay was used to quantify DNA-Topo I complexes. Results: Enhancement of radiation lethality was observed using confluent U1-Mel cells. The sensitizer enhancement ratio (SER) after a 4 h postirradiation exposure of 10 μM 9-AC was 2.5 at 10% survival. Toxicity from the drug alone was greater than topotecan (TPT), but less than CPT. The radiation synergy effect was: (a) dependent on drug concentration (≤ 2 μM); (b) dependent on timing, with enhancement present only when the drug was present at the time of, or shortly after, radiation; and (c) irreversible, with inhibition of PLDR. Exposure to 9-AC during or after irradiation substantially elevated the number of DNA- Topo I complexes (four- to tenfold) over control levels and correlated with enhanced loss of survival. Conclusion: 9-Aminocamptothecin enhanced radiation lethality in vitro at low drug concentrations with characteristics similar to other Topo I inhibitors. A greater SER, but greater lethality with the drug alone, was obtained in comparison to TPT. The clinical implications of these findings remain unexplored.

KW - 9-Aminocamptothecin

KW - DNA repair

KW - PLDR

KW - Topoisomerase I

UR - http://www.scopus.com/inward/record.url?scp=0030249357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030249357&partnerID=8YFLogxK

U2 - 10.1016/S0360-3016(96)00326-4

DO - 10.1016/S0360-3016(96)00326-4

M3 - Article

C2 - 8892462

AN - SCOPUS:0030249357

VL - 36

SP - 369

EP - 376

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 2

ER -